Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Exploration of new strategies for the prevention of breast cancer metastasis is justifiably at the center of clinical attention. In this study, we combined a computational biology approach with mechanism-based preclinical trials to identify inhibitors of activin-like receptor kinase (ALK) 1 as effective agents for blocking angiogenesis and metastasis in breast cancer. Pharmacologic targeting of ALK1 provided long-term therapeutic benefit in mouse models of mammary carcinoma, accompanied by strikingly reduced metastatic colonization as a monotherapy or part of combinations with chemotherapy. Gene-expression analysis of breast cancer specimens from a population-based nested case-control study encompassing 768 subjects defined endothelial expression of ALK1 as an independent and highly specific prognostic factor for metastatic manifestation, a finding that was corroborated in an independent clinical cohort. Overall, our results suggest that pharmacologic inhibition of endothelial ALK1 constitutes a tractable strategy for interfering with metastatic dissemination of breast cancer. Cancer Res; 75(12); 2445-56. ©2015 AACR.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Karolinska Institute
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
Originalspråkengelska
Sidor (från-till)2445-2456
TidskriftCancer Research
Volym75
Utgivningsnummer12
StatusPublished - 2015
PublikationskategoriForskning
Peer review utfördJa

Relaterad forskningsoutput

Matteo Bocci, 2018, Lund: Lund University, Faculty of Medicine. 174 s.

Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

Eleftheriou, N., 2017, Lund: Lund University, Faculty of Medicine. 58 s.

Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

Visa alla (2)